CN101676267B - N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 - Google Patents

N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 Download PDF

Info

Publication number
CN101676267B
CN101676267B CN2008101496511A CN200810149651A CN101676267B CN 101676267 B CN101676267 B CN 101676267B CN 2008101496511 A CN2008101496511 A CN 2008101496511A CN 200810149651 A CN200810149651 A CN 200810149651A CN 101676267 B CN101676267 B CN 101676267B
Authority
CN
China
Prior art keywords
compd
mesylate
salt
administration
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008101496511A
Other languages
English (en)
Chinese (zh)
Other versions
CN101676267A (zh
Inventor
袁开红
孙飘扬
周云曙
陈永江
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2008101496511A priority Critical patent/CN101676267B/zh
Application filed by Jiangsu Hengrui Medicine Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to US13/063,850 priority patent/US8362256B2/en
Priority to BRPI0919018A priority patent/BRPI0919018A2/pt
Priority to KR1020117008504A priority patent/KR101674227B1/ko
Priority to CA2736664A priority patent/CA2736664C/en
Priority to PCT/CN2009/072239 priority patent/WO2010031266A1/zh
Priority to JP2011526364A priority patent/JP5649132B2/ja
Priority to EP09813987.6A priority patent/EP2327697B1/en
Priority to MX2011002816A priority patent/MX2011002816A/es
Priority to AU2009295168A priority patent/AU2009295168B2/en
Priority to RU2011113229/04A priority patent/RU2499796C2/ru
Publication of CN101676267A publication Critical patent/CN101676267A/zh
Priority to HK10107871.7A priority patent/HK1141514B/xx
Priority to ZA2011/01891A priority patent/ZA201101891B/en
Application granted granted Critical
Publication of CN101676267B publication Critical patent/CN101676267B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CN2008101496511A 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐 Active CN101676267B (zh)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CN2008101496511A CN101676267B (zh) 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
RU2011113229/04A RU2499796C2 (ru) 2008-09-16 2009-06-11 Соли n-[4-(1-цианоциклопентил)фенил]-2-(4-пиридилметил)амино-3-пиридинкарбоксамида
KR1020117008504A KR101674227B1 (ko) 2008-09-16 2009-06-11 Ｎ-[4-(1-사이아노사이클로펜틸)페닐]-2-(4-피리딜메틸)아미노-3-피리딘카복스아마이드의 염
CA2736664A CA2736664C (en) 2008-09-16 2009-06-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
PCT/CN2009/072239 WO2010031266A1 (zh) 2008-09-16 2009-06-11 N-[4-(1-氰基环戊基)苯基]-2-（4-吡啶甲基）氨基-3-吡啶甲酰胺的盐
JP2011526364A JP5649132B2 (ja) 2008-09-16 2009-06-11 Ｎ−［４−（１−シアノシクロペンチル）フェニル］−２−（４−ピリジルメチル）アミノ−３−ピリジンカルボキサミドの塩
US13/063,850 US8362256B2 (en) 2008-09-16 2009-06-11 Salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridylmethyl)amino-3-pyridinecarboxamide
MX2011002816A MX2011002816A (es) 2008-09-16 2009-06-11 Sales de n-[4-(1-cianociclopentil)fenil]-2-(4-piridimetil) amino-3-piridinacarboxamida.
AU2009295168A AU2009295168B2 (en) 2008-09-16 2009-06-11 The salts of N-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
BRPI0919018A BRPI0919018A2 (pt) 2008-09-16 2009-06-11 sal farmaceuticamente aceitável, uso de sal, e, processo para a preparação de sal
EP09813987.6A EP2327697B1 (en) 2008-09-16 2009-06-11 The salts of n-(4-(1-cyanocyclopentyl)phenyl)-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
HK10107871.7A HK1141514B (en) 2010-08-18 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
ZA2011/01891A ZA201101891B (en) 2008-09-16 2011-03-11 The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101496511A CN101676267B (zh) 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐

Publications (2)

Publication Number Publication Date
CN101676267A CN101676267A (zh) 2010-03-24
CN101676267B true CN101676267B (zh) 2012-12-26

Family

ID=42029001

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008101496511A Active CN101676267B (zh) 2008-09-16 2008-09-16 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐

Country Status (12)

Country Link
US (1) US8362256B2 (enExample)
EP (1) EP2327697B1 (enExample)
JP (1) JP5649132B2 (enExample)
KR (1) KR101674227B1 (enExample)
CN (1) CN101676267B (enExample)
AU (1) AU2009295168B2 (enExample)
BR (1) BRPI0919018A2 (enExample)
CA (1) CA2736664C (enExample)
MX (1) MX2011002816A (enExample)
RU (1) RU2499796C2 (enExample)
WO (1) WO2010031266A1 (enExample)
ZA (1) ZA201101891B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381436A (zh) * 2017-08-14 2019-02-26 江苏恒瑞医药股份有限公司 阿帕替尼药物组合物及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104086483A (zh) * 2014-07-08 2014-10-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐f晶型及其制备方法和应用
CN104072410B (zh) * 2014-07-08 2017-02-08 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐d晶型及其制备方法和应用
CN104086484B (zh) * 2014-07-08 2016-05-25 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐溶剂化物晶体及其制备方法和应用
CN104072411A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐c晶型及其制备方法和应用
CN104072413A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐a晶型及其制备方法和应用
CN104072412A (zh) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用
CN105622499A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105622498A (zh) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
CN105541708A (zh) * 2014-10-28 2016-05-04 华东理工常熟研究院有限公司 硫酸阿帕替尼的新晶型
EP3283560B1 (en) 2015-04-15 2019-11-13 Dow Global Technologies LLC Thermally insulating foam with vertically elongated cells
CN105801476A (zh) * 2016-04-13 2016-07-27 上海宣创生物科技有限公司 阿帕替尼甲磺酸盐ii晶型及其制备方法和应用
CN106243031B (zh) * 2016-07-26 2017-09-08 江苏恒瑞医药股份有限公司 一种阿帕替尼的制备方法
TWI764943B (zh) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
EP3549608A4 (en) * 2016-12-01 2020-08-12 Jiangsu Hengrui Medicine Co., Ltd. USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER
CN108250138A (zh) * 2016-12-28 2018-07-06 上海宣创生物科技有限公司 阿帕替尼a晶型及其制备方法和应用
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用
CN109394685B (zh) * 2017-08-15 2021-04-06 江苏恒瑞医药股份有限公司 一种vegfr抑制剂的药物组合物及其制备方法
WO2019034048A1 (zh) * 2017-08-15 2019-02-21 江苏恒瑞医药股份有限公司 一种vegfr抑制剂晶型及其制备方法
US20200282052A1 (en) * 2017-11-10 2020-09-10 Elevar Therapeutics, Inc. A combination therapy with apatinib for the treatment of cancer
JP2021505548A (ja) 2017-12-06 2021-02-18 江蘇恒瑞医薬股▲ふん▼有限公司 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるｐａｒｐ阻害剤の使用
CN109942487A (zh) * 2017-12-21 2019-06-28 江苏恒瑞医药股份有限公司 一种吡啶类化合物及其制备方法、用途
BR112020011796A2 (pt) 2017-12-29 2020-11-17 Jiangsu Hengrui Medicine Co., Ltd. uso de tratamento combinado de anticorpo pd-1 e apati-nib para o tratamento de câncer de mama negativo triplo
US11434202B2 (en) 2018-09-05 2022-09-06 Assia Chemical Industries Ltd. Crystalline polymorphs of Rivoceranib and Rivoceranib mesylate
CN115279405B (zh) * 2020-04-10 2025-02-18 江苏恒瑞医药股份有限公司 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1502608A (zh) * 2002-11-27 2004-06-09 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001930D0 (en) * 2000-01-27 2000-03-22 Novartis Ag Organic compounds
KR20050026535A (ko) * 2002-07-31 2005-03-15 쉐링 악티엔게젤샤프트 Ｖｅｇｆｒ-2 및 ｖｅｇｆｒ-3 억제성 안트라닐아미도피리딘
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1502608A (zh) * 2002-11-27 2004-06-09 南京凯衡科贸有限公司 具有抑制血管生成活性的六员氨基酰胺类衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
说明书第8、18页.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381436A (zh) * 2017-08-14 2019-02-26 江苏恒瑞医药股份有限公司 阿帕替尼药物组合物及其制备方法

Also Published As

Publication number Publication date
CA2736664C (en) 2016-05-24
EP2327697A4 (en) 2012-06-06
HK1141514A1 (en) 2010-11-12
MX2011002816A (es) 2011-04-05
BRPI0919018A2 (pt) 2015-12-08
WO2010031266A1 (zh) 2010-03-25
EP2327697A1 (en) 2011-06-01
KR101674227B1 (ko) 2016-11-08
AU2009295168B2 (en) 2014-02-13
JP2012502885A (ja) 2012-02-02
RU2499796C2 (ru) 2013-11-27
RU2011113229A (ru) 2012-10-27
KR20110059877A (ko) 2011-06-07
US20110184023A1 (en) 2011-07-28
ZA201101891B (en) 2012-05-30
US8362256B2 (en) 2013-01-29
AU2009295168A1 (en) 2010-03-25
CA2736664A1 (en) 2010-03-25
EP2327697B1 (en) 2014-03-12
JP5649132B2 (ja) 2015-01-07
CN101676267A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
CN101676267B (zh) N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
US20200190033A1 (en) Crystalline Solid Forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, Processes for Making, and Methods of Use
CN107115318A (zh) 包含稳定的、无定形杂化纳米颗粒的药物组合物
JP7319383B2 (ja) マルチターゲットキナーゼ阻害剤、医薬組成物、並びにマルチターゲットキナーゼ阻害剤の製造方法及び適用
KR20190110581A (ko) 암 치료
CN102786469B (zh) 邻吡啶酰肼衍生物及其制法和药物组合物与用途
Lu et al. Polymorphs and pseudopolymorphs of Lenvatinib mesylate: crystal structure, equilibrium solubility, and stability study
CN117903141B (zh) 一种化合物及其盐、在制备治疗癌症药物和激酶抑制剂中的用途、治疗癌症的药物
WO2013107225A1 (zh) N-（（4-氯-3-三氟甲基）苯基）-n'-（2-氟-4-（（2-羟甲基氨基甲酰基)-4-吡啶基氧）苯基）脲及其作为抗癌药物的应用
WO2023098848A1 (zh) 奥希替尼共晶及制备方法以及作为药物或在药物制剂中的应用
CN109265444A (zh) 取代的三嗪类idh抑制剂的光学异构体及其应用
HK1141514B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
TWI462738B (zh) Ｎ－〔４－（１－氰基環戊基）苯基〕－２－（４－吡啶甲基）胺基－３－吡啶甲醯胺的鹽
CN119569705B (zh) Ptk抑制剂a的磷酸盐及应用
CN114957137B (zh) N-(1,2,3,6-四氢嘧啶-4-基)-2-苯基乙酰胺类化合物及其制备与应用
TW200536529A (en) Dosage forms and methods of treatment using VEGFR inhibitors
CN101230037A (zh) 一种抗癌药物化合物及其合成方法
Larocque et al. Nicotinamide-Ponatinib, HSN748, a Potent Anti-CML and Anti-AML Compound with Better Kinase Selectivity than Ponatinib
NZ723714B2 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141514

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1141514

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: HENGRUI PHARMACEUTICAL CO., LTD., SHANGHAI

Effective date: 20130717

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 222002 LIANYUNGANG, JIANGSU PROVINCE TO: 222047 LIANYUNGANG, JIANGSU PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20130717

Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222002 No. 145, Renmin East Road, Sinpo District, Jiangsu, Lianyungang

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160914

Address after: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Patentee after: Jiangsu Shengdi Pharmaceutical Co.,Ltd.

Address before: 222047 Kunlun Road, Lianyungang economic and Technological Development Zone, Jiangsu, No. 7

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240906

Address after: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee after: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Country or region after: China

Patentee after: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Address before: 222047 No. 7 Kunlun Shan Road, Lianyungang economic and Technological Development Zone, Jiangsu

Patentee before: JIANGSU HENGRUI MEDICINE Co.,Ltd.

Country or region before: China

Patentee before: SHANGHAI HENGRUI PHARMACEUTICAL Co.,Ltd.

Patentee before: Jiangsu Shengdi Pharmaceutical Co.,Ltd.